Non-Muscle Invasive Urothelial Carcinoma
Advertisement
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Dr. Ferguson highlights the latest TAR-210 and TAR-200 data in select patients with non-muscle invasive bladder cancer.
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
The guidelines included recommendations for treatment with TURBT and postoperative intravesical chemotherapy.
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
The trial indicated a "favorable risk/benefit ratio and quality of life" associated with the treatment.
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Nadofaragene firadenovec-vncg is now fully available for health care providers to prescribe across the US for NMIBC.
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
Dr. Lerner shares his thoughts on the results of ENVISION and the potential for UGN-102 for lg/ir NMIBC.
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.
The panel delves into treatment pathways, including considerations for ablation and repeated histologic evaluation.
The panel kicked off with conversations about risk stratification and classification of low-grade, intermediate-risk disease.
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.